Evidence map›Paper›PMID 32694616›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.

Chi Young Ok, Kevin T Trowell, Kyle G Parker, Karen Moser, Olga K Weinberg, Heesun J Rogers, Kaaren K Reichard, Tracy I George, Eric D Hsi, Carlos E Bueso-Ramos and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Chi Young OkDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6822-7880
Kevin T TrowellDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kyle G ParkerDepartment of Pathology, University of Chicago, Chicago, IL, USA.
Karen MoserDepartment of Pathology, University of Utah/ARUP Laboratories, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-2258-4444
Olga K WeinbergDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Heesun J RogersDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-8491-224X
Kaaren K ReichardDepartment of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Tracy I GeorgeDepartment of Pathology, University of Utah/ARUP Laboratories, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0001-5478-7847
Eric D HsiDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-8623-4067
Carlos E Bueso-RamosDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wayne TamDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0003-4283-0005
Attilio OraziDepartment of Pathology, Texas Tech Health Sciences Center, El Paso, TX, USA.
Adam BaggDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniel A ArberDepartment of Pathology, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2160-9689
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Sa A WangDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. swang5@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USARUP Laboratories (United States) · USCleveland Clinic · USUniversity of Chicago · USUniversity of Pennsylvania · USBoston Children's Hospital · USCornell University · USMassachusetts General Hospital · USMayo Clinic in Arizona · USTexas Tech University Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

JAK2, CALR, and MPL are myeloproliferative neoplasm (MPN)-driver mutations, whereas SF3B1 is strongly associated with ring sideroblasts (RS) in myelodysplastic syndrome (MDS). Concomitant mutations of SF3B1 and MPN-driver mutations out of the context of MDS/MPN with RS and thrombocytosis (MDS/MPN-RS-T) are not well-studied. From the cases (<5% blasts) tested by NGS panels interrogating at least 42 myeloid neoplasm-related genes, we identified 18 MDS/MPN-RS-T, 42 MPN, 10 MDS, and 6 MDS/MPN-U cases with an SF3B1 and an MPN-driver mutation. Using a 10% VAF difference to define "SF3B1-dominant," "MPN-mutation dominant," and "no dominance," the majority of MDS/MPN-RS-T clustered in "SF3B1-dominant" and "no dominance" regions. Aside from parameters as thrombocytosis and ≥15% RS required for RS-T, MDS also differed in frequent neutropenia, multilineage dysplasia, and notably more cases with <10% VAF of MPN-driver mutations (60%, p = 0.0346); MPN differed in more frequent splenomegaly, myelofibrosis, and higher VAF of "MPN-driver mutations." "Gray zone" cases with features overlapping MDS/MPN-RS-T were observed in over one-thirds of non-RS-T cases. This study shows that concomitant SF3B1 and MPN-driver mutations can be observed in MDS, MPN, and MDS/MPN-U, each showing overlapping but also distinctively different clinicopathological features. Clonal hierarchy, cytogenetic abnormalities, and additional somatic mutations may in part contribute to different disease phenotypes, which may help in the classification of "gray zone" cases.

Indexed as

AdultAgedAged, 80 and overCalreticulinFemaleHumansJanus Kinase 2MaleMiddle AgedMutationMyelodysplastic-Myeloproliferative DiseasesPhosphoproteinsReceptors, ThrombopoietinRNA Splicing FactorsCalreticulinCALR protein, humanJAK2 protein, humanJanus Kinase 2MPL protein, humanPhosphoproteinsReceptors, ThrombopoietinRNA Splicing FactorsSF3B1 protein, human

Identifiers

PMID32694616
OpenAlexW3045475835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.